ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

JAGX vs NEUP // EV/EBITDA & P/E VALUATION

Jaguar Health Inc. (NASDAQ) VS. Neuphoria Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: JAGX 2 — NEUP 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (JAGX VS. NEUP) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC JAGX NEUP SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 67.20% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -11.80% -23.20 NEUP /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — 0.47% — TIE /fcf-yield <GO>
Operating Margin -60.00% -7.20% -52.80 NEUP /operating-margins <GO>
Net Profit Margin -0.50% -2.40% +1.90 JAGX /net-margins <GO>
Revenue Growth (YoY) -1.50% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 5/9 -4.00 NEUP /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 39.6 25.4 +14.21 JAGX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $15.9M $16.6M -$642.4K NEUP /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR JAGX REV NEUP REV JAGX GROSS % NEUP GROSS % JAGX FCF NEUP FCF
FY 2025 $11.5M $15.6M 67.2% — -$23.7M $77.2K
FY 2024 $11.7M $0 83.3% — -$29.4M -$14.7M
FY 2023 $9.8M $0 — — -$33.2M -$14.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
JAGX // BETA —
NEUP // BETA —